Pharmaceutical composition and administrations thereof

A pharmaceutical composition consisting of:

• about 35 wt % of a solid dispersion by weight of the composition, wherein the dispersion comprises about 80 wt % of substantially amorphous or amorphous N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide by weight of the dispersion, about 19.5 wt % of HPMCAS by weight of the dispersion, and about 0.5 wt % SLS by weight of the dispersion;
• about 13.5 wt % of mannitol by weight of the composition;
• about 41 wt % of lactose by weight of the composition;
• about 2 wt % of sucralose by weight of the composition;
• about 6 wt % of croscarmellose sodium by weight of the composition;
• about 1 wt % of colloidal silicon dioxide by weight of the composition;
• and
• about 1.5 wt % of magnesium stearate by weight of the composition.